Immunology and Infectious Disease Commons^™

Implementation Of A Drive-Through Covid-19 Mass Vaccination Site: Experiences From Louvax–Broadbent In Louisville, Kentucky, Ruth Carrico, Sarah Beth Hartlage, Valenchia Brown Msn, Aprn, Fnp-C, Sarah M. Bishop, Luanne Didelot, William Hayden, Beverly Williams Coleman, Sarah Tan, Delanor Manson, Kellie Kane, Dawn Balcom, Paul Kern

The University of Louisville Journal of Respiratory Infections

Background: Response to the COVID-19 pandemic has required innovative approaches to vaccination, including methods to rapidly and safely immunize communities. A major challenge to such a response involved access to untapped healthcare worker resources. The Louisville, Kentucky, response involved the use of a large volunteer workforce to supplement local public health employees in planning and implementing a large-scale drive-through vaccination event. The objective of this manuscript was to outline processes involved in training a mass immunization workforce and implementating a large-scale COVID-19 community vaccination.

Approach: Competency-based and standardized training was provided for every volunteer before working their shift. Volunteers worked …

Q-Griffithsin Interactions And Utility For The Prevention And Treatment Of Mucosal Infections., Henry Nabeta

Electronic Theses and Dissertations

Griffithsin (GRFT) is a carbohydrate binding agent (lectin) that was originally identified in the red alga Griffithsia sp. Q-Griffithsin (Q-GRFT) is an oxidation stable analog of GRFT. GRFT has demonstrated inhibitory activity against HIV-1, Coronaviruses, Hepatitis C, influenza and Ebola viruses. The broad-spectrum activity suggests the potential utility of this lectin in a wide range of viral infections. However, the lectin’s activity in mucosal infections has not been extensively studied. Using in vitro, ex vivo and in vivo assays, we have demonstrated that Q-GRFT maintains the ability to bind glycosylated ligands following incubation in murine, macaque and human rectal …

Covid-19 And The Unseen Benefits Of Dexamethasone, Muhammad Arif Khan, Ikram Ullah, Dawood Ahmed

The University of Louisville Journal of Respiratory Infections

According to current World Health Organization (WHO) updates, the COVID-19 pandemic has spread all over the globe, affecting 216 countries, and has caused 8,860,331 confirmed cases and 465,740 deaths as of June 24, 2020. Many countries cannot afford nucleic acid tests to confirm COVID-19 infection; as a result, people cannot know the COVID-19 status of the people living around them. The use of dexamethasone in COVID-19 hospitalized patients for up to 10 days lowered 28-day mortality compared to patients receiving standard of care plus mechanical ventilation at randomization (by 12.3 age-adjusted percentage points, approximately one-third of proportional reduction) and patients …

Convalescent Plasma Therapy In Coronavirus Disease 2019 (Covid-19) Patients: A Brief Review, Muhammad Arif Khan, Ikram Ullah

The University of Louisville Journal of Respiratory Infections

The recent outbreak of the COVID-19 pandemic has caused a re-evaluation of the effectiveness of convalescent plasma therapy (CPT). This review was carried out to assess the usefulness of CPT in critically ill COVID-19 patients based on the published data to date. To the best of our knowledge, this is the second review of the usefulness of CPT in COVID-19 patients. PubMed, Google Scholar, MEDLINE, and Embase databases were searched for relevant reports up to June 21, 2020. Records of published data were analyzed according to eligibility criteria. Five different studies on CPT for critically ill COVID-19 patients were included …